《大行報告》麥格理下調微創醫療(00853.HK)目標價至42.57元 評級「跑輸大市」
麥格理發表報告,將微創醫療(00853.HK)2021年至2023年的每股盈利預測分別下調11%、50%、260%。
目標價由53.38元下調至42.57元,維持評級「跑輸大市」。
麥格理指,雖然微創醫療上半年手術量有所恢復,但鑒於Delta變種病毒對海外業務的影響和即將到來的骨科集中採購(GPO)存不確定性,管理層的全年指引變得更加保守,僅預計銷售增長將達到之前20%至27%的指引下限。骨科業務增長指引從25%至30%下調至15%至20%,以反映預期從第三季度開始GPO的潛在分銷商去庫存。麥格理對中國骨科業務看法仍然較負面,並預計未來三年的年複合增長率僅為11%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.